<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885322</url>
  </required_header>
  <id_info>
    <org_study_id>1344169-8</org_study_id>
    <nct_id>NCT04885322</nct_id>
  </id_info>
  <brief_title>Effects of PFC tDCS on Cognitive Control, Attention Lapses and Coordinated Neural Activity in the Theta and Alpha Bands</brief_title>
  <official_title>Effects of PFC tDCS on Cognitive Control, Attention Lapses and Coordinated Neural Activity in the Theta and Alpha Bands</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand the neural correlates of higher-order&#xD;
      cognition, both in the healthy brain and in schizophrenia, and to determine how these&#xD;
      mechanisms are modulated by transcranial direct current stimulation (tDCS) at frontal and&#xD;
      occipital scalp sites. Testing the effects of tDCS at these scalp sites on cognitive task&#xD;
      performance will help us understand the roles of the brain regions corresponding to these&#xD;
      sites during higher-order cognitive processing (language comprehension, cognitive control,&#xD;
      and related attention and memory processes). Behavioral and electrophysiological (EEG)&#xD;
      measures will be used to assess cognitive performance. Our overarching hypothesis is that&#xD;
      stimulating prefrontal circuits with tDCS can improve cognitive control performance, and&#xD;
      ultimately performance on a range of cognitive tasks, as compared to stimulating a different&#xD;
      cortical region (occipital cortex) or using sham stimulation.&#xD;
&#xD;
      This study is solely intended as basic research in order to understand brain function in&#xD;
      healthy individuals and individuals with schizophrenia. This study is not intended to&#xD;
      diagnose, cure or treat schizophrenia or any other disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">July 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 19, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Behavioral Cognitive Control Measures on the Stroop Task</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Incongruent versus Congruent difference in error rate and reaction time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EEG Cognitive Control Measures on the Stroop Task</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>response-locked power in the theta frequency band (4-7 Hz)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral Attention Lapse Measures on the Stroop Task</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Error Rate on Incorrect Congruent trials (Full Lapses) and Slow-but-Correct Congruent trials (Partial Lapses)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EEG Attention Lapse Measures on the Stroop Task EEG Attention Lapse Measures on the Stroop Task</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Pre-trial power in the alpha frequency band (8-12 Hz)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral Cognitive Control Measures on the Change Detection Task Behavioral Cognitive Control Measures on the Change Detection Task</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>WM storage capacity (k-max)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EEG Cognitive Control Measures on the Change Detection Task</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>delay period power in the theta frequency band (4-7 Hz)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Behavioral Attention Lapse Measures on the Change Detection Task</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Attention factor (a); Guess factor (g)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EEG Attention Lapse Measures on the Change Detection Task</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Pre-trial power in the alpha frequency band (8-12 Hz)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Delivered tDCS Dose to PFC</measure>
    <time_frame>Through study completion, an average of 1 month</time_frame>
    <description>Estimated electric field in PFC region of interest</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DLPFC Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Occipital Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Direct Current Stimulation</intervention_name>
    <description>In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area. The targeted brain area is determined by the Study Arm.</description>
    <arm_group_label>DLPFC Stimulation</arm_group_label>
    <arm_group_label>Occipital Stimulation</arm_group_label>
    <arm_group_label>Sham Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  between ages of 18 and 50&#xD;
&#xD;
          -  ability to sufficiently speak and understand English so as to be able to understand&#xD;
             and complete cognitive tasks&#xD;
&#xD;
          -  ability to give valid informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no history of head trauma&#xD;
&#xD;
          -  no current or previous history of treatment with psychotropic medication&#xD;
&#xD;
          -  corrected vision 20/30 or better&#xD;
&#xD;
          -  tDCS/MRI contraindications, including: pregnancy, ferrous metal in any part of the&#xD;
             body, serious medical conditions, claustrophobia, metallic implants, skin damage,&#xD;
             conditions such as eczema at electrode sites, cranial pathologies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michelle Galat</last_name>
    <phone>1-916-734-8779</phone>
    <email>mcgalat@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Imaging Research Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Zarubin, BS/BA</last_name>
      <phone>916-734-3749</phone>
      <email>vczarubin@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Cameron Carter, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

